Overview
Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in March 2009 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.
On 24 January 2006, orphan designation (EU/3/05/348) was granted by the European Commission to Intercell AG, Austria, for purified inactivated Japanese encephalitis SA14-4-2 virus vaccine for the prevention of Japanese encephalitis.
Key facts
Active substance |
Purified inactivated Japanese encephalitis SA14-4-2 virus vaccine
|
Intended use |
Prevention of Japanese encephalitis
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/05/348
|
Date of designation |
24/01/2006
|
Sponsor |
Intercell AG
Campus Vienna Biocenter 3 A-1030 Vienna Austria Telephone: +43 1 20 62 03 03 Telefax: +43 1 20 62 08 10 E-mail: orphandrug@intercell.com |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: